Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC44H40N6O7 |
InChIKeyBHITUPVYCSSRTP-HJYWNDIWSA-N |
CAS Registry- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | United States | 15 Sep 2023 | |
Neoplasms | Preclinical | United States | 15 Sep 2023 |